Optimi

Optimi CEO Dane Stevens discusses how MDMA & psilocybin are already being used in regulated clinical settings for PTSD & treatment-resistant depression. Real-world psychedelic therapy is taking shape. empoweredpatientpodcast.com/psychedelic-me… #MentalHealth #PsychedelicMedicine $OPTHF $OPTI

New research suggests psychedelics like psilocybin and MDMA may support long-term PTSD recovery by promoting repair of myelin — the insulating layer around nerve cells that helps stabilize brain circuits after treatment. nrtimes.co.uk/psychedelics-m… #MentalHealth $OPTHF $OPTI

HHS Secretary RFK Jr. says the Trump administration is “very anxious” to create a pathway for psychedelic therapy access in controlled settings, particularly for PTSD & depression. marijuanamoment.net/trump-administ… #MentalHealth #PsychedelicMedicine #HealthcarePolicy $OPTHF $OPTI

New Hampshire’s House approved a bipartisan bill to legalize regulated psilocybin therapy for PTSD, treatment-resistant depression & substance use disorders. marijuanamoment.net/new-hampshire-… #MentalHealth #PsychedelicMedicine $OPTHF $OPTI

Optimi Health Reports Early Clinical Rollout of Natural Psilocybin Capsules for TreatmentResistant Depression in Australia. Click here to learn more: s3.amazonaws.com/b2icontent.irp… #Psilocybin #Depression #PTSD $OPTHF $OPTI

The next wave of research is focused on separating therapeutic neuroplasticity from the hallucinogenic experience, potentially making treatments safer and more accessible for patients with unmet mental health needs. drugdiscoverynews.com/the-next-wave-… #MentalHealthInnovation $OPTHF $OPTI

Optimi Health Completes Psilocybin Export to Australia for Treatment Resistant Depression. Click here for details: s3.amazonaws.com/b2icontent.irp… #Australia #PTSD #MAMA $CABI

Big pharma is making decisive moves into psychedelic therapeutics. As institutional interest grows, the focus on regulated, pharmaceutical-grade solutions continues to strengthen. reuters.com/legal/transact… #MentalHealth #HealthcareInvesting #PsychedelicMedicine $OPTHF $OPTI

Optimi Health Completes MDMA Export for PTSD Treatment Under Australia's Authorised Prescriber Scheme. Click here to learn more: s3.amazonaws.com/b2icontent.irp… #MDMA #PTSD #Treatment $OPTHF $OPTI

The landscape for psychedelic therapies is evolving fast in 2026. As millions turn to self-medication and clinical research accelerates, there’s a clear opportunity for safe, pharmaceutical-grade approaches to meet patient needs responsibly. nature.com/articles/s4138… $OPTHF $OPTI

Momentum at the policy level reflects a growing recognition that current mental health tools are not enough. The need for safe, regulated, pharmaceutical-grade psychedelic therapies for patients with unmet needs is becoming increasingly clear. #Psychedelics $OPTHF $OPTI

The psychedelic medicine market is gaining serious momentum. This expanding landscape for regulated psychedelic therapies underscores rising opportunity and demand in mental health innovation. 🔗 geneonline.com/breakthrough-o… #MentalHealthInnovation #PsychedelicMedicine $OPTHF $OPTI

Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules. Click here to learn more: #b2iLibScrollTo" target="_blank" rel="nofollow noopener">optimihealth.ca/#b2iLibScrollTo #MDMA #Psilocybin $OPTI $OPTHF

🌍 International Expansion in Regulated Psychedelics @Optimi_Health (CSE: $OPTI | OTCQX: $OPTHF) is a GMP compliant pharmaceutical grade manufacturer of #MDMA and #Psilocybin. CEO Dane Stevens is here to tell us the #OptimiHealth story and how the company is leveraging market trends to drive growth. ▶️ Watch the recording here >> youtu.be/zWm1bnR_vZA #PsychedelicMedicine #ClinicalPsychedelics #Biopharma #DrugDevelopment #PsychedelicTherapy #MentalHealthInnovation

Optimi Health to Present at the Sidoti Micro-Cap Conference on January 21-22, 2026. Click here to learn more: s3.amazonaws.com/b2icontent.irp… #Conference #Sidoti #MicroCap $OPTI $OPTHF

Optimi Health CEO Dane Stevens joined The Wall Street Resource to discuss Optimi’s GMP-compliant pharmaceutical manufacturing platform, Health Canada licensing, and prescription use in Australia and Canada. thewallstreetresource.com/webcasts/ #Healthcare #GMP #MentalHealth $OPTHF $OPTI

The administration is preparing an order to reclassify marijuana from Schedule I to Schedule III — a major step toward easing research barriers and modernizing federal policy. Optimi Health welcomes evidence-based progress. Article: washingtonpost.com/business/2025/… $OPTHF $OPTI

Optimi Health Announces Appointment of New Director. Click here to learn more: #b2iLibScrollTo" target="_blank" rel="nofollow noopener">optimihealth.ca/#b2iLibScrollTo $OPTI $OPTHF

The Czech Republic just approved medical psilocybin starting in 2026 — a major step for evidence-based psychedelic therapy. Optimi Health is proud to support global progress toward safe, regulated access for patients who need new options. france24.com/en/live-news/2… $OPTI $OPTHF

A new clinical overview of psychedelic therapy in 2025 shows strong long-term results for PTSD with MDMA-assisted therapy and promising remission rates in depression with psilocybin. Read here: globalrph.com/2025/10/psyche… #PsychedelicTherapy #PTSD #DepressionResearch $OPTHF $OPTI